NO20082386L - Ligander som har bindingsspesifisitet for EGFR og/eller VEGF og fremgangsmater for anvendelse derav - Google Patents

Ligander som har bindingsspesifisitet for EGFR og/eller VEGF og fremgangsmater for anvendelse derav

Info

Publication number
NO20082386L
NO20082386L NO20082386A NO20082386A NO20082386L NO 20082386 L NO20082386 L NO 20082386L NO 20082386 A NO20082386 A NO 20082386A NO 20082386 A NO20082386 A NO 20082386A NO 20082386 L NO20082386 L NO 20082386L
Authority
NO
Norway
Prior art keywords
ligands
egfr
vegf
methods
binding specificity
Prior art date
Application number
NO20082386A
Other languages
English (en)
Norwegian (no)
Inventor
Haiqun Liu
Steve Holmes
Laurent S Jespers
Rudolf M T De Wildt
Armin Sepp
Olga Ignatovich
Roland Beckmann
Michael Steward
Malgorzata Pupecka
Original Assignee
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domantis Ltd filed Critical Domantis Ltd
Publication of NO20082386L publication Critical patent/NO20082386L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20082386A 2005-12-06 2008-05-26 Ligander som har bindingsspesifisitet for EGFR og/eller VEGF og fremgangsmater for anvendelse derav NO20082386L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74299205P 2005-12-06 2005-12-06
US75835506P 2006-01-11 2006-01-11
PCT/GB2006/004559 WO2007066106A1 (en) 2005-12-06 2006-12-05 Ligands that have binding specificity for egfr and/or vegf and methods of use therefor

Publications (1)

Publication Number Publication Date
NO20082386L true NO20082386L (no) 2008-08-27

Family

ID=37820653

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082386A NO20082386L (no) 2005-12-06 2008-05-26 Ligander som har bindingsspesifisitet for EGFR og/eller VEGF og fremgangsmater for anvendelse derav

Country Status (13)

Country Link
US (2) US20100056439A1 (es)
EP (1) EP1966242A1 (es)
JP (1) JP2009518024A (es)
KR (1) KR20080077261A (es)
AU (1) AU2006323412A1 (es)
BR (1) BRPI0619463A2 (es)
CA (1) CA2632417A1 (es)
CR (1) CR10024A (es)
EA (1) EA013878B1 (es)
MA (1) MA30021B1 (es)
NO (1) NO20082386L (es)
TW (1) TW200804425A (es)
WO (1) WO2007066106A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
GB0621513D0 (en) 2006-10-30 2006-12-06 Domantis Ltd Novel polypeptides and uses thereof
GB0724331D0 (en) * 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
CA2697032C (en) 2007-08-22 2021-09-14 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
AU2008328726B2 (en) * 2007-11-30 2014-06-12 Glaxo Group Limited Antigen-binding constructs
CN102131827A (zh) * 2007-12-13 2011-07-20 葛兰素集团有限公司 用于肺部传递给药的组合物
CA2711256C (en) 2008-01-03 2019-01-15 The Scripps Research Institute Antibody targeting through a modular recognition domain
US8454960B2 (en) * 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
KR20100132535A (ko) 2008-03-31 2010-12-17 글락소 그룹 리미티드 약물 융합체 및 컨주게이트
EP2268668A1 (en) 2008-04-17 2011-01-05 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
EP2346526A2 (en) 2008-09-22 2011-07-27 Massachusetts Institute of Technology Compositions of and methods of using ligand dimers
BRPI0919714A2 (pt) * 2008-10-21 2015-12-08 Domantis Ltd domínio variável único de imunoglobulina, polipeptídeo isolado, ligante, ácido nucleico, vetor, célula hospedeira, e, método para produzir um polipeptídeo
CN102224169A (zh) * 2008-11-26 2011-10-19 葛兰素集团有限公司 多肽、抗体可变结构域和拮抗剂
US20100189651A1 (en) 2009-01-12 2010-07-29 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
CN102405236A (zh) * 2009-02-19 2012-04-04 葛兰素集团有限公司 改进的抗-tnfr1多肽，抗体可变结构域和拮抗剂
JP5861223B2 (ja) 2009-02-23 2016-02-16 サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. プロタンパク質およびその使用方法
US9394374B2 (en) * 2009-05-28 2016-07-19 Glaxo Group Limited Antigen-binding proteins
JP2012532620A (ja) * 2009-07-16 2012-12-20 グラクソ グループ リミテッド 改良型抗血清アルブミン結合単一可変ドメイン
CN102781959A (zh) 2010-02-05 2012-11-14 埃博灵克斯股份有限公司 能够结合血清白蛋白的肽和包含所述肽的化合物、构建体和多肽
US9029328B2 (en) 2010-03-24 2015-05-12 The Brigham And Women's Hospital, Inc. Methods for cardioprotection and cardioregeneration with dimers of EGF family ligands
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
JP2013537421A (ja) * 2010-08-20 2013-10-03 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 改良された抗血清アルブミン結合変異体
US20130236467A1 (en) * 2010-11-24 2013-09-12 Jeremy Griggs Multispecific antigen binding proteins targeting hgf
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
EP2777707A1 (en) 2013-03-11 2014-09-17 Wake Forest University Health Sciences Method of Treating Brain Tumors
BR112015023752B1 (pt) 2013-03-15 2023-11-14 Zyngenia, Inc. Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
CN105814082A (zh) * 2013-09-26 2016-07-27 埃博灵克斯股份有限公司 双特异性纳米抗体
JP7001474B2 (ja) 2015-01-21 2022-01-19 インヒブルクス，インコーポレイティド 非免疫原性単一ドメイン抗体
EP3253790A4 (en) * 2015-02-06 2018-07-25 University of Maryland, Baltimore Tetra-specific, octameric binding agents and antibodies against clostridium difficile toxin a and toxin b for treatment of c. difficile infection
NZ777930A (en) 2015-07-16 2025-05-02 Inhibrx Biosciences Inc Multivalent and multispecific dr5-binding fusion proteins
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
EP3768722A4 (en) * 2018-03-19 2021-12-29 Wuxi Biologics Ireland Limited. Novel anti-egfr antibody polypeptide
WO2020204305A1 (ko) * 2019-03-29 2020-10-08 주식회사 녹십자 항-메소텔린 항체, 항-cd3 항체 또는 항-egfr 항체를 포함하는 융합 단백질 및 이를 포함하는 이중 특이적 또는 삼중 특이적 항체 및 이의 용도
US12043652B2 (en) 2020-08-28 2024-07-23 Trustees Of Boston University Engineered extracellular receptor constructs and uses thereof
CN115724968B (zh) * 2021-08-27 2023-08-08 三优生物医药(上海)有限公司 Vegf结合分子及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ292061B6 (cs) * 1994-03-17 2003-07-16 Merck Patent Gmbh Jednořetězcové fragmenty protilátek a protilátky proti receptoru epidermálního růstového faktoru, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
DE69735292T2 (de) * 1996-10-25 2006-10-19 Gilead Sciences, Inc., Foster City Gefaesszellen wachstumsfaktor (vegf) nukleinsäureligand-komplexe
JP3957765B2 (ja) * 1997-04-07 2007-08-15 ジェネンテク・インコーポレイテッド 抗ｖｅｇｆ抗体
US6699473B2 (en) * 2000-10-13 2004-03-02 Uab Research Foundation Human anti-epidermal growth factor receptor single-chain antibodies
RU2295537C2 (ru) * 2000-10-20 2007-03-20 Тугаи Сейяку Кабусики Кайся Модифицированное агонистическое антитело
US7667004B2 (en) * 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
ES2263984T3 (es) * 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
WO2004041867A2 (en) * 2002-11-08 2004-05-21 Ablynx N.V. Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders
WO2005044858A1 (en) * 2003-11-07 2005-05-19 Ablynx N.V. Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
AU2003290330A1 (en) * 2002-12-27 2004-07-22 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
CN1845938B (zh) * 2003-06-30 2010-05-26 杜门蒂斯有限公司 多肽
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US20090252681A1 (en) * 2005-10-11 2009-10-08 Ablynx N.V. Nanobodies and Polypeptides Against EGFR and IGF-IR

Also Published As

Publication number Publication date
EP1966242A1 (en) 2008-09-10
US20130041136A1 (en) 2013-02-14
BRPI0619463A2 (pt) 2013-01-08
EA013878B1 (ru) 2010-08-30
WO2007066106A1 (en) 2007-06-14
JP2009518024A (ja) 2009-05-07
CR10024A (es) 2008-09-22
TW200804425A (en) 2008-01-16
EA200801172A1 (ru) 2008-12-30
KR20080077261A (ko) 2008-08-21
CA2632417A1 (en) 2007-06-14
MA30021B1 (fr) 2008-12-01
US20100056439A1 (en) 2010-03-04
AU2006323412A1 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
NO20082386L (no) Ligander som har bindingsspesifisitet for EGFR og/eller VEGF og fremgangsmater for anvendelse derav
NO20082960L (no) Ligander med bindingsspesifisitet for VEGF og/eller EGFR og fremgangsmater for anvendelse derav
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
LTC2100614I2 (lt) Antikūnas prieš PDGFR-alfa, skirtas naudoti auglių gydymui
SG170793A1 (en) Anti-mn antibodies and methods of using same
WO2007149482A3 (en) Xanthohumol based protein kinase modulation cancer treatment
WO2018226578A8 (en) Nectin-4 binding proteins and methods of use thereof
NO20083127L (no) Fremgangsmater og preparater for malretting av polyubiquitin
WO2008140493A3 (en) Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
NO20083147L (no) Anti-OX40L-antistoffer og fremgangsmater for anvendelse av disse
EA200702278A1 (ru) Антитела, специфичные в отношении tgf-бета 1
WO2009009173A3 (en) Klotho-beta for use in treating cancer, liver disorders, gallstones, wasting syndrome and obesity-related diseases
NO20064194L (no) Fremgangsmate for a modulere IL-23-aktivitet, beslektede reagenser
ATE424159T1 (de) Katheter
EP2134854A4 (en) METHOD OF TREATMENT USING EGFR ANTIBODIES AND CRS INHIBITORS, AND RELATED FORMULATIONS
NO20070950L (no) Preparater og fremgangsmater for anvendelse av angiopoietinlignende-4-protein.
CY1114658T1 (el) Πρωτεϊνες δεσμευσης αντιγονου του αυξητικου παραγοντα τυπου επιδερμικου αυξητικου παραγοντα προσδεσης στην ηπαρινη
ATE461220T1 (de) Anti-egfr-antikörper
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
MY148763A (en) Anti-5t4 antibodies and uses thereof
NO20083593L (no) Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse
WO2008151819A3 (en) Treatment of tumors using specific anti-l1 antibody
DK1782070T3 (da) Tumorassocieret antigenprofiler i cancerdiagnostik og immunterapi
WO2010009171A3 (en) Src activation for determining cancer prognosis and as a target for cancer therapy